
- SAN FRANCISCO (AFX) -- Teva Pharmaceutical Industries Ltd. after Monday's closing bell said the Food and Drug Administration has granted final approval for the company's abbreviated new drug application to market its generic version of Forest Laboratories Inc.'s Lexapro tablets, a treatment for depression. Teva added that it is in patent litigation concerning this product in the U.S. District Court for the District of Delaware.
Forest Laboratories is the US partner of Danish pharmaceutical group H Lundbeck AS. newsdesk@afxnews.com jfr COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
© 2006 AFX News